Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. RYDAPT
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

RYDAPT

Medicine - Posted on Mar 04 2021
Active substance (DCI)
  • midostaurine
history (4)
  • 2/17/21

    RYDAPT (midostaurine)

    Key points Favourable opinion for maintenance of reimbursement, as monotherapy, for the treatment of adult patients with agg...
    CAV :
    54321
    icône flèche
  • Economic analysis
    6/27/18

    RYDAPT (midostaurin), tyrosine kinase inhibitor

    Low clinical benefit in the treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis associated with a sec...
    CAV :
    54321
    icône flèche
  • Economic analysis
    6/13/18

    RYDAPT (midostaurine), tyrosine kinase inhibitor

    High clinical benefit in the treatment of newly diagnosed acute myeloid leukaemia with FLT3 gene mutation, combined with che...
    CAV :
    54321
    icône flèche
  • 10/3/18

    RYDAPT (midostaurine)

    Mise à disposition d’une présentation en boîte de 56 capsules en complément des boîtes de 112 capsules. ...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XE39
Manufacturer
NOVARTIS PHARMA S.A.S.
Presentation

RYDAPT 25 mg, capsule molle (code CIS : 67868413)
Conditionnements multiples de 56 (2 boîtes de 28) capsules sous plaquettes polyamide aluminium PVC-Aluminium (CIP : 34009 301 298 2 1)
Conditionnements multiples de 112 (4 boîtes de 28) capsule(s) sous plaquette(s) polyamide aluminium PVC (CIP : 34009 301 136 0 8)

All our publications
    Blood and lymphatic diseases - miscellaneous Congenital, genetic and rare diseases Drug therapy Hematologic cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
ng6r7ae5GuBTPerV